• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    RxSight, Inc. - Common Stock (NQ:RXST)

    9.370 +0.760 (+8.83%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about RxSight, Inc. - Common Stock

    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 Next >
    RxSight, Inc. to Participate in the 34th Annual Oppenheimer Healthcare Conference
    From RxSight, Inc.
    Via GlobeNewswire
    Forecasting The Future: 9 Analyst Projections For RxSight
     
    Via Benzinga
    Recap: RxSight Q4 Earnings
     
    Via Benzinga
    RxSight, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
    From RxSight, Inc.
    Via GlobeNewswire
    RxSight, Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
    From RxSight, Inc.
    Via GlobeNewswire
    Stifel Maintains Buy Rating for RxSight: Here's What You Need To Know
     
    Via Benzinga
    The Analyst Landscape: 8 Takes On RxSight
     
    Via Benzinga
    Earnings Scheduled For February 28, 2024
    Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. 
    Via Benzinga
    RxSight's Earnings Outlook
     
    Via Benzinga
    Breaking Down RxSight: 5 Analysts Share Their Views
     
    Via Benzinga
    Analyst Expectations for RxSight's Future
     
    Via Benzinga
    RxSight: Q3 Earnings Insights
     
    Via Benzinga
    Insiders are selling these hot stocks on track for higher prices
    Insiders are selling these hot stocks and may cap gains in the near term, but long-term gains are in the outlook. Analysts support them and raise their targets. 
    Via MarketBeat
    Jim Cramer: This Healthcare Stock Is 'Too Risky,' But Shares Jumped 64% Over Past Month
    On CNBC’s "Mad Money Lightning Round," Jim Cramer said Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is "too risky." 
    Via Benzinga
    3 Stocks to Buy BEFORE They Become Household Names
    The best way to find 100 baggers is to invest in undiscovered stock gems that have yet to become household names. 
    Via InvestorPlace
    RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Financial and Operational Results and 2024 Guidance
    From RxSight, Inc.
    Via GlobeNewswire
    Where RxSight Stands With Analysts
     
    Via Benzinga
    RxSight's Earnings: A Preview
     
    Via Benzinga
    The Latest Analyst Ratings for RxSight
     
    Via Benzinga
    Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on... 
    Via Benzinga
    RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference
    From RxSight, Inc.
    Via GlobeNewswire
    RxSight, Inc. Reports Third Quarter 2023 Financial Results
    From RxSight, Inc.
    Via GlobeNewswire
    RxSight, Inc. Educational and Product Announcements for AAO 2023
    From RxSight, Inc.
    Via GlobeNewswire
    RxSight, Inc. to Report Third Quarter Financial Results on November 9, 2023
    From RxSight, Inc.
    Via GlobeNewswire
    RxSight, Inc. to Present at the Wells Fargo Healthcare Conference
    From RxSight, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
     
    Via Benzinga
    RxSight, Inc. Reports Second Quarter 2023 Financial Results
    From RxSight, Inc.
    Via GlobeNewswire
    RxSight, Inc. to Report Second Quarter Financial Results on August 7, 2023
    From RxSight, Inc.
    Via GlobeNewswire
    RxSight Is A Potential Acquisition Target: Analyst Highlights How LAL Revenue Mix Could Drive Share Price To $45+
    Needham analyst David Saxon reiterated a Buy rating on RxSight, Inc. (NASDAQ: RXST),  
    Via Benzinga
    RxSight, Inc. Reports First Quarter 2023 Financial Results
    From RxSight, Inc.
    Via GlobeNewswire
    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.